Predictive Oncology Inc

NASDAQ:POAI

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. The company is headquartered in Eagan, Minnesota and currently employs 30 full-time employees. The company went IPO on 2009-12-18. The firm provides predictive models of tumor drug response that are used to improve clinical outcomes for patients. The company operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment includes clinical testing and contract research services that include the application of AI. zPREDICTA specializes in organ-specific disease models that provide 3D reconstruction of human tissues, accurately representing each disease state and mimicking drug response, enabling accurate testing of anticancer agents. The Soluble segment provides services using a self-contained, automated system that conducts throughput, self-interaction chromatography screens using additives and excipients commonly included in protein formulations, resulting in soluble and physically stable formulations for biologics. The Skyline segment consists of the STREAMWAY System product sales.